On October 28, Nanjing Hicin Pharmaceutical (300584.SZ) announced that the company recently received the Drug Supplement Application Approval Notice issued by the National Medical Products Administration, and Voglibose tablets passed the evaluation of generic drug quality and efficacy consistency.

Voglibose tablets are oral antidiabetic drugs, belonging to α-glucosidase inhibitors. They inhibit α-glucosidase in the intestine, delaying the digestion and absorption of sugars, and improving postprandial hyperglycemia. This product is mainly used to improve postprandial hyperglycemia in diabetic patients (applicable when patients receiving dietary therapy, exercise therapy have not achieved significant effects, or when patients in addition to dietary therapy, exercise therapy also use oral hypoglycemic drugs or insulin preparations and have not achieved significant effects). Voglibose tablets were first developed by Takeda Pharmaceutical, with two specifications of 0.2mg and 0.3mg. They were launched in Japan in 1994 under the brand name BASEN, and in China in 1998 under the name Beixin. Voglibose tablets are now on the market in multiple countries. According to the State Drug Administration website, apart from the company, Tianjin Takeda, Jiangsu Chenpai, Nanjing Hicin Pharmaceutical, Peking Shuanglu, Zhejiang Jingxin, and many other companies have been approved. This product is comparable in efficacy to acarbose, with a wider range of applications, fewer gastrointestinal side effects, and higher clinical value.